Evidence map›Paper›PMID 34652076›Full record

ArticleJournal of breast cancer2021

Jia-Ni Pan, Lei Lei, Wei-Wu Ye, Xiao-Jia Wang, Wen-Ming Cao

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy forInternational journal of molecular sciences · 2025
    Review
  3. Clinical case reports · 2023
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jia-Ni PanDepartment of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.ORCID https://orcid.org/0000-0002-8357-9358
Lei LeiDepartment of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.ORCID https://orcid.org/0000-0002-6838-4050
Wei-Wu YeDepartment of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.ORCID https://orcid.org/0000-0001-5720-976X
Xiao-Jia WangDepartment of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.ORCID https://orcid.org/0000-0002-7005-0842
Wen-Ming CaoDepartment of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.ORCID https://orcid.org/0000-0002-5644-3156
Chinese Academy of Sciences · CNZhejiang Chinese Medical University · CN

Funding

Key Research-Development Program of Zhejiang ProvinceKey Research-Development Program of Zhejiang Province 2019C04001Key Research-Development Program of Zhejiang Province 2020C04012Natural Science Foundation of Zhejiang Province LY21H160005
6 · The paper itself

Abstract

Reversion mutations are associated with clinical resistance to poly(ADP-ribose) polymerase inhibitors (PARPi). Here, we describe the detection of a

Indexed as

Breast neoplasmsCirculating tumor DNAHigh-throughput nucleotide sequencingPoly(ADP-ribose) polymerase inhibitors

Identifiers

PMID34652076
PMCPMC8561137
OpenAlexW3201368220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.